Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Treanda bendamustine: Phase III data

In an open-label, single-arm Phase III trial in 100 patients with relapsed, rituximab-refractory N HL, Treanda met the co-primary endpoints

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE